A Comparative Review of GI and ID Guidelines for Clostridioides difficile Treatment

Clostridioides difficile infection (CDI) is a leading healthcare-associated infection, primarily affecting older adults and patients with recent antibiotic exposure. Gastroenterology (GI) and infectious disease (ID) societies have developed separate guidelines reflecting their respective focuses. This review compares recommendations from the American College of Gastroenterology (ACG), Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA), and the American Gastroenterological Association (AGA). Both ACG and IDSA/SHEA endorse multistep diagnostic algorithms combining sensitive and specific assays, though IDSA permits PCR-only testing under strict criteria. For initial CDI, vancomycin and fidaxomicin are first-line agents, with IDSA’s 2021 update prioritizing fidaxomicin for reduced recurrence. Recurrent CDI management is similar, emphasizing fidaxomicin, tapered vancomycin, and fecal microbiota transplantation (FMT) after multiple recurrences. ACG and AGA provide greater specificity for FMT use and endorse microbiota-based therapies earlier in high-risk or treatment-refractory patients. Both guidelines (e.g., ACG and IDSA/SHEA) align on definitions and treatment for severe and fulminant CDI but diverge on prophylactic vancomycin and management in inflammatory bowel disease. Overall, the recommendations are largely concordant, with GI guidelines emphasizing fecal microbiota therapies and individualized care. Trials of defined synthetic consortia of bacteria are underway and may further alter the treatment landscape. Clinical trials and experience with these agents will inform future prevention and treatment algorithms as we move toward the safest and most effective therapeutic strategies for CDI.